RxDoctor Payments Data

Lindsay Malatesta

Neuromuscular Medicine · Nashville, TNNPI 1629430996

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $18,931 of the $24,463 with a category attached, or 77.4%. AstraZeneca accounts for 75.0% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $19,114, more than ten times the $40 reported in 2022.

$24,463in general payments, 2019–2025

Across 58 payments — averaging $421.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$18K
  • Biogen$3K
  • Johnson & Johnson$2K
  • UCB, Inc.$725
  • Argenx US, Inc.$250
  • Janssen Scientific Affairs, LLC$172
  • plus $119 from 1 others

What the payments were for

  • Consulting fees$18,93177%
  • Travel & lodging$3,00112%
  • Food & beverage$2,3119%
  • Education$2191%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few neuromuscular medicine providers in Tennesseeto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$33,423
Medicare patients
159
Services billed
336

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyvgartEfgartigimod Alfa-Fcab18$649,518
SkyclarysOmaveloxolone12$374,782
Radicava OrsEdaravone25$355,484
RelyvrioSod Phenylbutyrat/Taurursodiol11$144,015
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5013$130,136
Riluzole68$11,626
Pyridostigmine Bromide ErPyridostigmine Bromide14$6,614
Pyridostigmine Bromide82$6,035
Mycophenolate Mofetil15$5,150
Azathioprine23$2,801
Prednisone110$2,060
Glycopyrrolate26$1,361
Atropine Sulfate44$1,354
Gabapentin49$1,177
Baclofen53$1,167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Argenx US, Inc.Vyvgart$250$649,51818 claims
BiogenSkyclarys$2,526$374,78212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromuscular medicine providers in Tennesseeon file to place this against a meaningful peer group, so we don't.

Other neuromuscular medicine in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →